Skip to main content
Morepen Laboratories Ltd. logo

Morepen Laboratories Ltd. — Investor Relations & Filings

Ticker · MOREPENLAB ISIN · INE083A01026 LEI · 335800OJZDFHFQJ4HP35 BSE.NS Manufacturing
Open in API
Filings indexed 1,660 across all filing types
Latest filing 2023-06-29 Regulatory Filings
Country IN India
Listing BSE.NS MOREPENLAB

About Morepen Laboratories Ltd.

https://www.morepen.com

Morepen Laboratories Ltd. is a research-led company specializing in the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), home diagnostic devices, and finished formulations. The company maintains a significant global presence, exporting high-quality APIs such as Loratadine, Montelukast, Atorvastatin, and Fexofenadine to numerous international markets. Its diagnostic division, branded as Dr. Morepen, is a prominent player in the home healthcare segment, offering a wide range of products including digital glucometers, blood pressure monitors, and nebulizers. Morepen operates manufacturing facilities compliant with international regulatory standards, including USFDA approvals. The company focuses on leveraging its R&D capabilities to deliver healthcare solutions and maintains a diverse portfolio across various therapeutic areas including cardiovascular, anti-diabetic, and anti-asthmatic treatments.

Recent filings

Filing Released Lang Actions
Trading Window
Regulatory Filings Classification · 95% confidence The document is a notification addressed to stock exchanges about the closure of the trading window due to the upcoming announcement of unaudited financial results for the quarter ended June 30, 2023. It references SEBI regulations on insider trading and trading restrictions around financial results announcements. The document does not contain any financial data or results itself, nor does it provide a report or detailed financial analysis. It is a regulatory compliance announcement related to trading restrictions before earnings release. Given the short length (1914 characters) and the nature of the content, this is not a financial report but a regulatory filing informing about trading window closure. Therefore, the appropriate classification is Regulatory Filings (RNS).
2023-06-29 English
Closure of Trading Window with effect from 1st July 2023 till 48 hours after the announcement of financial results.
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges regarding the closure of the trading window pursuant to SEBI regulations ahead of the announcement of unaudited financial results for the quarter ended June 30, 2023. It is an announcement about the trading window closure and does not contain any financial data or results itself. The document length is short (1914 characters) and it serves as a notification rather than a report. Therefore, it is not an Interim/Quarterly Report (IR) or Earnings Release (ER), but rather a Regulatory Filing (RNS) as it is a compliance-related announcement that does not fit other specific categories.
2023-06-29 English
Loss of Share Certificates
Regulatory Filings
2023-06-27 English
Issuance of letter of confirmation against duplicate share certificates.
Regulatory Filings
2023-06-27 English
Loss of Share Certificates
Regulatory Filings
2023-06-23 English
Pursuant to the Regulation 39(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, please find attached herewith ....
Regulatory Filings
2023-06-23 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.